Clarivate Plc (CLVT)
After hours:
| Previous close | 6.90 |
| Open | 7.00 |
| Bid | 6.70 x 3000 |
| Ask | 7.15 x 3000 |
| Day's range | 6.87 - 7.09 |
| 52-week range | 5.19 - 9.61 |
| Volume | |
| Avg. volume | 4,530,029 |
| Market cap | 4.698B |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.65 |
| Earnings date | 06 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.72 |
PR NewswireClarivate Director Richard Roedel to Retire from Board of Directors
Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Richard Roedel will retire from the Board of Directors (the "Board") for health reasons, effective December 31, 2024. The Board expects Valeria Alberola, a member of the Board since May 2021, and a member of its Audit and Finance Committees, to succeed Mr. Roedel as Chair of the Audit Committee.
- PR Newswire
Clarivate Acquires Rowan TELS to Enhance Support for Patent Practitioners
Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it has acquired Rowan TELS Corp. through a subsidiary. Rowan TELS Corp. is the provider of Rowan Patents – an integrated patent drafting and prosecution solution specially designed for patent practitioners to establish and protect patents more effectively.
- PR Newswire
BioWorld by Clarivate Celebrates Nine Wins at 2024 APEX Awards
BioWorld™ published by Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, has been honored with nine 2024 APEX Awards for Publication Excellence. This achievement underscores the BioWorld mission to deliver superior journalistic excellence, data-driven analysis and cutting-edge digital publishing.
